Cited by 16Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentDevelopmental and Educational Neuropsychology

Analysis of individual items on the attention-deficit/hyperactivity disorder symptom rating scale in children and adults: the effects of age and sex in pivotal trials of lisdexamfetamine dimesylate

Open access
Weisler, Richard, Childress, AC, Adler, Lenard, Kollins, Scott, Goodman, David, Hamdani, Dirks, Bryan·2013·Neuropsychiatric Disease and Treatment

Abstract

BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children and adults with ADHD to elucidate differences in participant presentation. The response to treatment was examined to determine patterns of response among items of the ADHD Rating Scale IV. METHODS: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were conducted on data from two 4-week placebo-controlled trials in children (6-12 years) and in adults (18-55 years) with ADHD. Baseline and endpoint mean item scores were determined for subgroups defined by age (6-9, 10-12, 18-39, and 40-55 years) and sex. RESULTS: The baseline mean item scores were generally numerically similar for all age-by-sex subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity (H/I) items among older children and adults. The endpoint mean item scores were numerically lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups. CONCLUSION: These results suggest that regardless of age or sex, baseline IA and H/I symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after active treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s47087

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a post hoc analysis of Biederman et al, at week 6 compared with placebo, LDX was associated with significantly lower DBQ errors (P < .02) and lapses (P < .02).

    “At week 6, compared with placebo, LDX was associated with significantly lower DBQ errors (P < .02) and lapses (P < .02).”

    From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [44]

    The Methods (Study overview; page unavailable) describe two 4-week trials, and the reported outcomes are ADHD-RS-IV item scores, not DBQ errors or lapses. Searches for “DBQ errors lapses week 6” and “Biederman driving behavior questionnaire” found no passage reporting the claimed week-6 comparison or P values. (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • In the same post hoc analysis, a decrease in DBQ violations was noted, although not significant (P = .16).

    “A decrease in DBQ violations was also noted, although not significant (P = .16).”

    From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [44]

    The Methods (Statistical analyses; page not provided) describe a post hoc analysis of ADHD-RS-IV symptom items, and the Results (Participants; page not provided) report changes in those items. Searches for DBQ violations, driving behavior, and P = .16 found no passage addressing the claimed outcome. (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [11]American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, Fourth Edition. Text Revision Arlington, VA American Psychiatric Association 2000

Cited by

Sorted by citations

Authors
Weisler, R., Childress, A., Adler, L., Kollins, S., Goodman, D., Hamdani, & Dirks, B.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • VA NY Harbor Healthcare System (US)
  • Duke Medical Center (US)
  • Johns Hopkins University (US)
Corresponding author
Weisler, Richard
Venue
Neuropsychiatric Disease and Treatment
Published
2013-12
Volume
10
Pages
1
ISSN
1176-6328 (ISSN-L)
OpenAlex
W1967848183
Cited by
16
References
41
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 1 · 2014: 1
FWCI
1.19
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • UNC Libraries
Funders
  • Eli Lilly and Company
  • Pfizer
  • Purdue University
  • Sunovion
  • York University
  • Shionogi
  • National Institutes of Health
  • National Institute on Drug Abuse
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
Keywords
attention deficit hyperactivity disorder, lisdexamfetamine dimesylate, ADHD Rating Scale-IV, inattention, hyperactivity/impulsivity, age differences, sex differences, children, adults, treatment response, presenting symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review